(NASDAQ: RZLT) Rezolute's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 62.56%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.25%.
Rezolute's earnings in 2026 is -$84,228,000.On average, 12 Wall Street analysts forecast RZLT's earnings for 2026 to be -$68,328,147, with the lowest RZLT earnings forecast at -$77,840,497, and the highest RZLT earnings forecast at -$49,236,459. On average, 12 Wall Street analysts forecast RZLT's earnings for 2027 to be -$65,696,461, with the lowest RZLT earnings forecast at -$91,908,057, and the highest RZLT earnings forecast at -$46,221,982.
In 2028, RZLT is forecast to generate -$32,211,841 in earnings, with the lowest earnings forecast at -$78,778,334 and the highest earnings forecast at $31,149,596.